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The liver-specific microRNA, miR-122, stabilizes
hepatitis C virus (HCV) RNA genomes by recruiting
host argonaute 2 (AGO2) to the 50 end and preventing
decaymediated by exonuclease Xrn1. However, HCV
replication requires miR-122 in Xrn1-depleted cells,
indicating additional functions. We show that miR-
122 enhances HCVRNA levels by altering the fraction
of HCV genomes available for RNA synthesis. Exog-
enous miR-122 increases viral RNA and protein
levels in Xrn1-depleted cells, with enhanced RNA
synthesis occurring before heightened protein syn-
thesis. Inhibiting protein translation with puromycin
blocks miR-122-mediated increases in RNA synthe-
sis, but independently enhances RNA synthesis by
releasing ribosomes from viral genomes. Addition-
ally, miR-122 reduces the fraction of viral genomes
engaged in protein translation. Depleting AGO2
or PCBP2, which binds HCV RNA in competition
with miR-122 and promotes translation, eliminates
miR-122 stimulation of RNA synthesis. Thus, by dis-
placing PCBP2, miR-122 reduces HCV genomes
engaged in translation while increasing the fraction
available for RNA synthesis.
INTRODUCTION
Hepatitis C virus (HCV) is an important human pathogen that in-
fects as many as 185 million persons worldwide, causing end-
stage liver disease and hepatocellular carcinoma (Thomas,
2013). Classified within the family Flaviviridae, it possesses an
uncapped, positive-sense, single-stranded RNA genome with
structured 50 and 30 untranslated regions (UTRs) flanking a large
open reading frame that encodes a polyprotein that is processed
into ten viral proteins (Scheel and Rice, 2013). The 50 UTR con-
tains an internal ribosome entry site (IRES) that mediates cap-in-
dependent initiation of viral protein synthesis and, at its extremeCell Host &50 end, RNA signals essential for genome replication (Friebe
et al., 2001; Honda et al., 1999). The 50 UTR serves as a platform
for recruitment of cellular factors that are essential for viral trans-
lation and/or RNA replication, including, among others, poly(rC)-
binding protein 2 (PCBP2), eukaryotic initiation factor 3 (eIF3),
and microRNA 122 (miR-122) (Fukushi et al., 2001; Jopling
et al., 2005; Kieft et al., 2001; Pestova et al., 1998; Wang et al.,
2011).
miR-122 is a highly expressed and liver-specific small RNA
that accounts for a large fraction of miRNAs in hepatocytes
(Chang et al., 2004). It regulates expression of numerous liver-
specific genes post-transcriptionally by binding to the 30 UTR
of cellular mRNAs (Chang et al., 2004; Lanford et al., 2010). In
contrast to this typical miRNA action, miR-122 binds to two
conserved sites (S1 and S2) near the 50 end of the HCV 50 UTR
and stimulates replication of the virus (Jangra et al., 2010; Jo-
pling et al., 2005, 2008). Mutations introduced into the S1 and
S2 sites that disrupt miR-122 binding severely impair replication
(Jangra et al., 2010; Jopling et al., 2005; Norman and Sarnow,
2010). However, S1 and S2 virus mutants can be rescued by
transfection of modified miR-122 oligonucleotides containing
complementary mutations that restore binding to the 50 UTR,
indicating that miR-122 promotes HCV replication directly and
not indirectly by modulating host gene expression. Silencing
miR-122 by administration of a complementary locked nucleic
acid (LNA) oligomer has shown therapeutic promise in preclinical
and clinical studies (Janssen et al., 2013; Lanford et al., 2010),
highlighting the importance of miR-122 in the virus life cycle.
Although well established, an understanding of how miR-122
promotes HCV replication has remained elusive. Early studies
suggested that it might act, in part, by stimulating IRES-directed
translation (Henke et al., 2008). Later work supports this view
(Jangra et al., 2010; Roberts et al., 2011; Zhang et al., 2012),
but recent data suggest that increases in viral protein expression
may result from an unusual stabilizing effect of miR-122 on the
HCV genome (Shimakami et al., 2012a). miR-122 recruits argo-
naute 2 (AGO2) protein to the 50 end of the viral RNA (Conrad
et al., 2013; Shimakami et al., 2012a) and protects the genome
from 50 decay mediated by the cytoplasmic 50 exonuclease,
Xrn1 (Li et al., 2013b). miR-122 and Xrn1 thus have competing ef-
fects on the stability and rate of decay of HCV RNA in infectedMicrobe 17, 217–228, February 11, 2015 ª2015 Elsevier Inc. 217
cells, and Xrn1 depletion enhances both viral RNA abundance
and the production of infectious virus in cell culture (Li et al.,
2013b). However, while miR-122 has no effect on the stability
of HCV RNA in Xrn1-depleted cells due to the absence of 50
exonuclease activity, supplementing such cells with exogenous
miR-122 continues to boost HCV replication (Li et al., 2013b).
Furthermore, Xrn1 depletion does not rescue replication of a viral
mutant that is defective in miR-122 binding (Li et al., 2013b).
These results indicate that miR-122 has an additional key func-
tion in the HCV replication cycle above and beyond its ability
to physically stabilize the genome (Li et al., 2013a). Consistent
with this, some miR-122 mutants protect RNA against Xrn1-
mediated decay, yet fail to promote virus replication (Mortimer
and Doudna, 2013).
Here, we demonstrate the direct involvement of miR-122 in
viral RNA synthesis. We show that augmenting endogenous
miR-122 abundance stimulates viral RNA synthesis under condi-
tions of Xrn1 depletion in which miR-122 has no effect on viral
RNA stability. While we find translation and replication of the viral
RNA are tightly coupled processes, miR-122-mediated in-
creases in RNA synthesis temporally precede increases in viral
protein synthesis. Surprisingly, however, miR-122 does not
stimulate viral RNA synthesis in the absence of active protein
translation or following RNAi-mediated depletion of PCBP2.
Our results indicate that the primary function of miR-122 is to
enhance HCV RNA synthesis, and suggest a mechanism by
which miR-122 alters the balance of viral genomes engaged in
genome synthesis versus protein translation.
RESULTS
miR-122 Supplementation Exerts a Primary Effect on
Viral RNA Synthesis
Although the positive influence of miR-122 on HCV genome
amplification is well known, it remains unclear whether its pri-
mary effect is on viral protein or viral RNA synthesis, two critical
steps in the viral life cycle. We thus compared the kinetics of
miR-122-mediated increases in the abundance of viral RNA
and viral proteins in HCV-infected cells in an effort to determine
whether one precedes the other and thus might represent a pri-
mary effect of miR-122. We supplemented the endogenous
abundance of miR-122 in HJ3–5 virus-infected cells by trans-
fecting synthetic duplex miR-122 or, as a control, a brain-spe-
cific miRNA, miR-124 (see Experimental Procedures). Because
miR-122 stabilizes genomic RNA by protecting it from Xrn1-
mediated decay (Li et al., 2013b), we examined the kinetics of
HCV RNA and protein accumulation both with and without prior
siRNA-mediated depletion of Xrn1 (Figure 1A). Xrn2, a predomi-
nantly nuclear 50 exonuclease, has also been suggested to
mediate HCV RNA decay (Sedano and Sarnow, 2014). However,
we found that Xrn2 depletion has no effect on the decay of HJ3–5
RNA, whereas Xrn1 depletion significantly slows it (Figures S1A–
S1D). Moreover, we confirmed that miR-122 supplementation
has only a minimal, non-significant effect on RNA decay in
Xrn1-depleted cells (Figures S1E and S1F) (Li et al., 2013b).
Nonetheless, miR-122 supplementation mediated significant
increases in viral RNA abundance and NS5A protein expression
in both Xrn1-depleted cells as well as in cells transfected with
a non-targeting siRNA, siCtrl (Li et al., 2013b) (Figure 1). As218 Cell Host & Microbe 17, 217–228, February 11, 2015 ª2015 Elseexpected (Li et al., 2013b), these increases were greater in siCtrl-
than in siXrn1-transfected cells (Figure 1). In multiple experi-
ments, increases in viral RNA and NS5A abundance occurred
with a similar kinetic and were significant within 6–9 hr following
transfection of miR-122 (Figures 1C and 1E). These results
demonstrate very close coupling between increases in viral
RNA synthesis and protein expression, but do not reveal which
is the primary target of miR-122.
Given this tight coupling between viral RNA and protein syn-
thesis, we developed methods to measure these processes
directly by metabolic labeling (Figure 2A). After confirming Xrn1
depletion (Figure 2B), cells were labeled with either 5-ethynyl uri-
dine (EU) or [35S]-methionine/cysteine following transfection with
miR-122 or the control miR-124. Nascent viral RNA was
measured by qRT-PCR following pull-down of biotin-conju-
gated, EU-labeled RNA (see Experimental Procedures). We
usedHJ3–5/NS5AYFP virus for these experiments as it expresses
NS5A with an internal yellow fluorescent protein (YFP) fusion,
allowing measurement of nascent protein synthesis by immuno-
precipitation of [35S]-labeled NS5A-YFP with anti-YFP antibody
followed by SDS-PAGE and phosphorimager analysis (Fig-
ure 2C). Remarkably, we observed a reproducible increase in
nascent viral RNA synthesis within 1 hr in cells transfected with
miR-122 versus miR-124, whereas there was no measurable in-
crease (and in fact a slight, but significant, decrease) in
NS5A-YFP synthesis during this period (Figure 2D; p < 0.01 by
two-sided Mann-Whitney test). Increased NS5A-YFP synthesis
was observed at later time points, likely because of increases
in viral RNA available for translation. Since the t1/2 of replicating
HJ3–5 RNA is approximately 8.3–9.6 hr in Xrn1-depleted cells
(Figure S1F), the increase in viral RNA synthesis at 1 hr cannot
be explained by enhanced RNA stability. Moreover, while
miR-122 appeared to protect newly synthesized RNA from
degradation, this effect was not observed in Xrn1-depleted cells
(Figure S2). Collectively, these data provide strong evidence that
miR-122 directly promotes HCV RNA synthesis, and confirm
close coupling between viral RNA and protein synthesis.
AGO2 is recruited to the 50 end of HCV RNA by miR-122, and
required for miR-122-mediated stabilization of HCV RNA and
amplification of viral RNA abundance (Conrad et al., 2013; Shi-
makami et al., 2012a). To determine whether AGO2 is also
required for miR-122 stimulation of viral RNA synthesis, we
transfected cells with AGO2-specific siRNA prior to miR-122
supplementation (Figure 2E). Consistent with our earlier findings
(Shimakami et al., 2012a), viral RNA synthesis was significantly
reduced in AGO2-depleted cells compared with cells trans-
fectedwith control siRNA (Figure 2F; p < 0.01). More importantly,
in contrast to the results shown in Figure 2D, there was no
increase in viral RNA synthesis during the first hour after miR-
122 transfection (Figure 2F). Thus, miR-122 stimulates RNA syn-
thesis in an AGO2-dependent fashion.
miR-122 Sequestration and Viral RNA Synthesis
Next, we considered whether sequestering miR-122 by trans-
fecting a complementary LNA antagomir of miR-122 would
have an effect opposite to miR-122 supplementation, reducing
HCV RNA synthesis in short-term experiments. Given that the
regulation of RNA synthesis by miR-122 requires AGO2 (Fig-
ure 2F), we first compared the kinetics with which miR-122vier Inc.
Figure 1. Kinetics of miR-122-Mediated Increases in RNA and Protein Abundance
(A) Experimental design; HJ3–5 virus-infected cells were transfectedwith scrambled control (siCtrl) or Xrn1-specific (siXrn1) siRNA and 2 days later re-transfected
with duplex miRNAs (0 hr), then harvested at the times indicated for assays of HCV RNA and NS5A protein.
(B) Immunoblots of Xrn1, NS5A, and core protein at 0 hr. b-actin was a loading control.
(C) HCV RNA abundance in cells transfected with siCtrl or siXrn1 and supplemented with miR-122 or miR-124. RNA was quantified by qRT-PCR relative to
b-actin mRNA.
(D) Immunoblots of NS5A protein in cells transfected with (top panels) siCtrl or (bottom panels) siXrn1 following miR-124 or miR-122 supplementation.
(E) NS5A expression was quantified based on infrared fluorescence intensities in immunoblots shown in (D) relative to b-actin expression. Results shown in (C)
and (E) represent mean fold change ± SEM from 0 hr in triplicate cultures and are representative of multiple independent experiments. *p < 0.05 (miR-122 versus
miR-124) by two-way ANOVAwith correction for multiple comparisons. miR-122-mediated increases in RNA and NS5A protein were greater in siCtrl-transfected
cells than Xrn1-transfected cells at 18 and 24 hr (p < 0.05). See also Figure S1.supplementation and sequestration modulate loading of the
miRNA into AGO2. AGO2 pull-down followed by qRT-PCR quan-
titation of co-immunoprecipitated miR-122 revealed that trans-
fection of miR-122 resulted in a 5- to 10-fold increase in
AGO2-bound miR-122 within 1 hr (Figure 3A). In contrast, trans-
fection of anti-miR-122 reduced the abundance of miR-122
bound to AGO2 by only 30% after 1 hr, and 90% only after
12 hr (Figure 3B).
In keeping with the slow kinetic with which sequestration re-
duces AGO2-bound miR-122, neither viral RNA nor NS5A-YFP
synthesis was reduced 0–1 or 3–6 hr after transfection of the
anti-miR-122 LNA (Figures 3C and 3D). However, both were
significantly reduced by 6–12 hr post-transfection (p = 0.03 for
NS5A-YFP, and p < 0.001 for HCV RNA, compared with cells
transfected with an anti-random control). Consistent with miR-
122 exerting its primary effect on viral RNA synthesis, the reduc-Cell Host &tion in nascent RNA was significantly greater than in nascent
NS5A-YFP (64% ± 6.9% SEM of anti-random control for RNA
versus 86% ± 5.6% for NS5A-YFP, p < 0.001).
miR-122 Does Not Stimulate Viral Translation
To directly assess how the abundance of miR-122 influences
HCV protein translation in the absence of ongoing viral RNA syn-
thesis, we treated stably infected cells with potent inhibitors of
the NS5B RNA-dependent RNA polymerase (Figure 4A). After
achieving high-level depletion of Xrn1 (Figure 4B), cells were
treated with PSI-6130 or sofosbuvir (SOF) for 14 hr, then trans-
fected with duplex miR-122 or miR-124 and HCV RNA and
NS5A-YFP synthesis quantified as described above. HCV RNA
synthesis was reduced to background levels by the NS5B inhib-
itors (Figure 4C, left), supporting the specificity of this assay.
Total HCV RNA was reduced, but still abundant, in the cellsMicrobe 17, 217–228, February 11, 2015 ª2015 Elsevier Inc. 219
Figure 2. miR-122 Directly Stimulates Nascent HCV RNA Synthesis
(A) Experimental design; HJ3–5/NS5AYFP virus-infected cells were transfected with siRNAs, then 2 days later, re-transfected with duplex miRNAs (0 hr) and
immediately fed with media containing 5-EU or [35S]-methionine/cysteine. Cells were harvested at intervals for quantitation of nascent HCV RNA and NS5A-YFP
as described in Experimental Procedures.
(B) Immunoblot of Xrn1 at the time of miRNA transfection from a representative experiment. b-actin is a loading control.
(C) Metabolically labeled [35S]-NS5A-YFP from a representative experiment. Cell lysates were immunoprecipitatedwith rabbit anti-GFP antibody (Anti-GFP, lanes
1–10) or with an isotype control (Ig, lanes 11 and 12). Immunoprecipitates were separated by SDS-PAGE, and labeled proteins visualized by phosphorimager
analysis. The labeling period (0–1 to 0–9 hr) is indicated near the top.
(D) Increases in 5-EU-labeled HCV RNA and [35S]-NS5A-YFP synthesis following miR-122 supplementation. 5-EU-labeled HCV RNA was precipitated and
quantified by qRT-PCR. [35S]-NS5A-YFP was quantified by phosphorimager analysis of SDS-PAGE gels. Results for both 5-EU-labeled HCV RNA and [35S]-
NS5A-YFP are shown as bars representing themean fold increase ± SEM in cells supplementedwithmiR-122 relative to cells supplementedwith the control miR-
124 for labeling periods ranging from 0–1 to 0–9 hr post-transfection. Individual results from replicate independent experiments are plotted as empty (HCV RNA)
or full (NS5A-YFP) symbols. **p < 0.01 by two-sided Mann-Whitney test.
(E) Immunoblot showing AGO2 abundance in cells transfected 96 and 48 hr previously with siAGO2 or siCtrl.
(F) Impact of miR-122 supplementation on nascent HCV RNA in cells depleted of AGO2. The 5-EU labeling period was from 0 to 1 hr following transfection of miR-
124 or miR-122. Results shown represent the mean ± SEM from triplicate cultures and are representative of multiple independent experiments. *p < 0.05 by two-
sided t test. See also Figure S2.(5 3 107 copies/mg total RNA) at the end of the 12-hr labeling
period (Figure 4C, right), and there was no difference in its abun-
dance in cells supplemented with miR-122 versus those trans-
fected with miR-124. This further confirms that miR-122 does
not have a stabilizing effect on HCV RNA in Xrn-1 depleted cells
(Li et al., 2013b). The amount of newly synthesized [35S]-labeled
NS5A-YFP protein was also reduced by the polymerase inhibi-
tors due to the reduction in RNA template available for translation
(Figure 4D). Most importantly, however, miR-122 supplementa-
tion caused only marginal, non-significant increases in NS5A-
YFP synthesis in thePSI-6130- andSOF-treated cells (Figure 4E).
These data are in agreement with a primary effect of miR-122 on
HCV RNA synthesis, and not viral protein translation.220 Cell Host & Microbe 17, 217–228, February 11, 2015 ª2015 ElsemiR-122 Stimulation of Viral RNA Synthesis Requires
Active Protein Translation
While translation of an incoming positive-strand RNA virus
genome is necessary to establish replication complexes and
initiate viral RNA synthesis in newly infected cells, prior studies
indicate that continued protein translation is not required for
ongoing HCV or flaviviral RNA synthesis (Shi et al., 2003; West-
away et al., 1999). This suggests that essential replicase compo-
nents are either recycled for new rounds of viral RNA synthesis,
or are present in excess abundance. To determine whether miR-
122 would induce increases in RNA synthesis in the absence of
ongoing translation, we treated infected Xrn1-depleted cells with
puromycin or cycloheximide (CHX) (Figures 5A and 5B). Bothvier Inc.
Figure 3. miR-122 Sequestration and Viral
RNA Synthesis
(A) qRT-PCR quantitation of miR-122 co-im-
munoprecipitating with AGO2 in cell lysates
prepared 1 hr after transfection of miR-122 (sup-
plementation) or miR-124 (control). Shown are the
mean ± SEM miR-122 copies per mg total protein
(used for immunoprecipitation) precipitated with
anti-AGO2 versus an irrelevant immunoglobulin
(Ig) from two independent experiments.
(B) AGO2-bound miR-122 abundance at various
intervals following transfection of the miR-122-
specific LNA antagomir (sequestration). Results
are shown as the mean ± SEM percent AGO2-
bound miRNA in cells transfected with anti-
random control.
(C) Nascent [35S]-NS5A-YFP recovered from
HJ3–5/NS5AYFP virus-infected cells labeled 0–1,
3–6, or 6–12 hr following transfection of the anti-
miR-122 antagomir or anti-random. Xrn1-depleted
cells were used in experiments involving labeling
periods beyond 1 hr. See legend to Figure 2C for
details.
(D) Reductions in nascent 5-EU-labeled HCV RNA
and [35S]-NS5A-YFP following miR-122 seques-
tration. Results are shown as the mean percent ±
SEM compared with cells transfected with anti-
random (n = 3–6). Labeling periods were 0–1, 3–6,
and 6–12 hr post-transfection, as in (C). **p < 0.01
by two-sided Mann-Whitney test.inhibitors caused a complete or near-complete inhibition of viral
and cellular protein synthesis without a noticeable effect on total
cellular protein abundance over the 5 hr course of the experiment
(Figure 5C). Surprisingly, short-term treatment (3–5 hr) with puro-
mycin increased nascent viral RNA synthesis asmuch as ormore
than miR-122 supplementation in the absence of puromycin
(Figure 5D). In contrast, there was no increase in nascent viral
RNA synthesis after 4-hr treatment with CHX (Figure 5E). This dif-
ference is likely due to puromycin-induced dissociation of trans-
lating ribosomes from viral RNA, as this would lead to increased
availability of viral RNA templates for RNA synthesis as observed
in vitro with poliovirus (Barton et al., 1999). In contrast, CHX
freezes ribosomes and prevents their clearance from RNA.
Even more surprising, however, miR-122 supplementation
had no effect on nascent viral RNA synthesis in cells treated
with either puromycin or CHX (Figures 5D and 5E). The lack of
miR-122 stimulation of RNA synthesis was not related to insuffi-
cient AGO2, as AGO2 abundance was minimally reduced
after 5 hr of translational shutoff (Figures S3A and S3B). More-
over, although reduced from untreated cells, miR-122 supple-
mentation substantially increased the quantity of miR-122 that
co-immunoprecipitated with AGO2 from lysates of puromycin-
treated cells (Figure S3C). Lengthier shutdown of protein synthe-
sis (12–15 hr), exceeding the estimated half-lives of nonstructural
HCV proteins (Pietschmann et al., 2001), significantly decreased
viral RNA synthesis in Xrn1-depleted cells and similarly elimi-
nated any enhancement of nascent viral RNA synthesis by
miR-122 (Figure S4). Collectively, these results confirm earlier
reports that continuing protein translation is not required for
HCV RNA synthesis as long as there is a sufficient abundance
of the requisite nonstructural proteins (Shi et al., 2003;WestawayCell Host &et al., 1999). In contrast, active protein translation is required for
miR-122 to stimulate HCV RNA synthesis.
miR-122 Rebalances RNA Engagement in Translation
versus RNA Synthesis
Since puromycin treatment and miR-122 supplementation
caused similar, non-additive increases in HCV RNA synthesis
(Figure 5D), we considered the possibility of a common underly-
ing mechanism. Puromycin increases poliovirus RNA synthesis
in cell-free replication reactions by clearing ribosomes from viral
RNA, thereby providingmore template for RNA synthesis (Barton
et al., 1999). A partial inhibition of HCV translation initiation by
miR-122 could have a similar impact on viral RNA synthesis.
To assess this possibility, we analyzed the distribution of HCV
RNA in rate-zonal gradients loaded with polysomes isolated
from infected cells 1–2 hr after transfection with miR-122 or the
control miR-124 (Figures 6 and S5). As anticipated, miR-122
induced a decrease in the proportion of HCV RNA associating
with polysomes engaged in translation (Figure 6A, fractions
11–13) and an increase in less translationally active RNA co-
sedimenting with 80S ribosomes (fractions 7–9) (Figure 6A).
These changes were less than those observed with puromycin
(Figure 6B), but they were reproducible and statistically signifi-
cant (p < 0.005). In contrast, no changes were evident in b-actin
mRNA distribution. Substantially smaller changes occurred in
the distribution of chloride intracellular channel 4 (CLIC4) and
cationic amino acid transporter 1 (CAT1) mRNAs within an
hour of transfecting miR-122, both natural targets of the miRNA
(Figure 6C). We conclude from these results that miR-122 in-
duces an immediate rebalancing of the proportion of viral RNA
engaged in translation versus that templating new viral RNAMicrobe 17, 217–228, February 11, 2015 ª2015 Elsevier Inc. 221
Figure 4. miR-122 and Viral Translation
following Arrest of HCV RNA Synthesis
(A) Experimental design; Huh-7 cells that were
stably infected with HJ3–5/NS5AYFP virus (see
Experimental Procedures) were transfected with
siRNAs and then treatedwith 50 mMof PSI-6130 or
10 mM of sofosbuvir (SOF) for 14 hr before trans-
fection of duplex miR-124 or miR-122 (0 hr). After
miRNA transfection, cells were incubated in
fresh culture media containing [35S]-methionine/
cysteine or 5-EU plus PSI-6130 or SOF for an
additional 12 hr before being harvested for assay
of nascent HCV RNA and NS5A-YFP.
(B) Immunoblot of Xrn1 60 hr following siRNA
transfection. b-actin is a loading control.
(C) Left: nascent HCV RNA synthesis in cells
transfected with miR-122 or miR-124 following
treatment with the NS5B inhibitors. ‘‘GND’’ cells
were electroporated with 10 mg of replication-
defective HJ3–5 NS5B/GND RNA 7 days prior to
the experiment. They contain no replication-
competent HCV RNA, and thus allow assessment
of background activity in the nascent RNA syn-
thesis assay. Results shown are means ± SEM
from triplicate cultures and are representative of
multiple independent experiments. Right: total
HCV RNA abundance at the end of the 12-hr
labeling period.
(D) NS5A-YFP synthesis following arrest of viral
RNA synthesis. Lysates of cells labeled with [35S]-
methionine/cysteine as in (A) were immunopre-
cipitated with anti-GFP or isotype control (Ig)
antibody, and precipitates separated by SDS-
PAGE. [35S]-labeled NS5A-YFP was visualized
with a phosphorimager.
(E) Phosphorimager quantitation of the effect
of miR-122 supplementation on labeled NS5A-
YFP protein in cells in which HCV RNA synthesis
was arrested with NS5B inhibitors. Results are shown as the fold increase in NS5A-YFP synthesis in miR-122-versus miR-124-transfected cells, and are
the mean ± SEM from triplicate cultures in a representative experiment. For all panels, **p < 0.01 by two-way ANOVA.synthesis. By 2 hr, the increase in newly synthesized RNA results
in a net increase in viral protein synthesis (Figure 2D), although
the redistribution of HCV RNA persists (Figure S6).
miR-122 Stimulation of Viral RNA Synthesis Is PCBP2
Dependent
In addition to miR-122/AGO2, several cellular proteins, including
the heterogeneous nuclear ribonuclear proteins PCBP2 (hnRNP
E2) and hnRNP L, bind to the 50 end of theHCV genome and facil-
itate its replication (Fukushi et al., 2001; Li et al., 2014; Wang
et al., 2011). PCBP2 is of particular interest, as it regulates the
IRES-initiated translation of poliovirus, another positive-strand
RNA virus, and facilitates both circularization and translation of
the HCV genome (Perera et al., 2007; Wang et al., 2011). Recent
studies in our laboratory also show that PCBP2 competes with
miR-122 for binding to synthetic RNA representing the 50
47 nts of HCV (Li et al., 2014) (Figure 7A). In similar pull-down ex-
periments, we found that a two-base change (nts 41–42) within
the S2 binding site of miR-122 ablated PCBP2, but not hnRNP
L, binding (Figure 7B). This confirms that a major PCBP2 binding
site overlaps one of the two functional miR-122 binding sites,
suggesting in turn that miR-122 might skew the engagement of
viral RNA molecules away from translation toward RNA synthe-222 Cell Host & Microbe 17, 217–228, February 11, 2015 ª2015 Elsesis by competing with and displacing PCBP2. Were this the
case, we reasoned that miR-122 supplementation would have
little if any positive effect on HCV RNA synthesis in cells depleted
of PCBP2. To test this hypothesis, we depleted stably infected
cells of PCBP2 by two successive transfections of PCBP2-
specific siRNA (Figures 7C and 7D). This resulted in modest re-
ductions in NS5A-YFP and HCV RNA abundance 48 hr after
the second siRNA transfection (83% ± 7% and 80% ± 4% of
siCtrl-transfected cells, p = 0.12 and p < 0.01, respectively) (Fig-
ures 7D and 7E). After transfecting the cells with miR-124 or miR-
122, we assessed nascent NS5A-YFP and HCV RNA synthesis
using the methods described above. In cells supplemented
with the control miRNA, miR-124, prior PCBP2 depletion
reduced NS5A-YFP synthesis to 82% ± 2% of that in control
cells (Figures 7F and 7G; p < 0.001). In contrast, there was no
reduction in viral RNA synthesis (103% ± 4%) (Figure 7H). This
suggests that PCBP2 depletion either increased the efficiency
of RNA synthesis or proportion of HCV RNAs engaged in viral
RNA synthesis. Furthermore, as anticipated, miR-122 supple-
mentation did not stimulate either viral protein or viral RNA syn-
thesis in PCBP2-depleted cells (Figures 7F–7H). We conclude
that miR-122 promotes new viral RNA synthesis, at least in
part, by displacing PCBP2 from the viral RNA, decreasing thevier Inc.
Figure 5. miR-122 Supplementation and Nascent HCV RNA following Short-Term Shutdown of Cellular Protein Synthesis
(A) Experimental design; HJ3–5/NS5AYFP virus-infected cells were transfected with siRNAs, and then treated 2 days later with 50 mg/ml puromycin or cyclo-
heximide for 2 hr prior to transfection of duplex miR-124 or miR-122 (0 hr). Following transfection of the miRNAs, cells were immediately fed with fresh media
containing 5-EU or [35S]-methionine/cysteine plus puromycin or cycloheximde for an additional 1–3 hr, then harvested for analysis of nascent viral RNA and
protein.
(B) Immunoblot of Xrn1 48 hr after siRNA transfection. b-actin is a loading control.
(C) Protein synthesis following treatment with puromycin (PUR) or cycloheximide (CHX). Cell lysates collected after various labeling periods were immunopre-
cipitated with anti-GFP or isotype control (Ig) antibody, and the precipitates separated by SDS-PAGE. Radiolabeled proteins were visualized with a phos-
phorimager (top and middle panels). Total protein expression was determined by Sypro Ruby staining (bottom panel). Results shown are representative of
multiple experiments.
(D) HCV RNA synthesis following shutdown of cellular translation. Total RNA was extracted from cells treated with puromycin at the times indicated, and 5-EU-
labeled HCV RNA quantified as described in Experimental Procedures.
(E) HCV RNA synthesis 2 hr after shutdown of cellular translation with cycloheximide (CHX). Results shown in (D) and (E) represent the mean quantity of nascent
viral RNA/mg total cellular RNA ± SEM in triplicate cultures, and are representative of multiple independent experiments. *p < 0.05 by two-way ANOVA. See also
Figures S3 and S4.fraction of viral RNAs engaged in translation and proportionally
increasing the fraction available to template viral RNA synthesis.
DISCUSSION
Although miR-122 was found to be an important host factor for
HCV almost a decade ago (Jopling et al., 2005), an understand-
ing of its role in the viral life cycle has remained elusive. Our pre-
viouswork indicates that the binding ofmiR-122 to two sites near
the 50 end of the viral genome stabilizes the RNA and protects it
within infected cells from 50 Xrn1-mediated decay (Li et al.,
2013b; Shimakami et al., 2012a). Although a recent report
suggested that Xrn2, a predominantly nuclear 50 exonuclease,
mediates HCV RNA decay (Sedano and Sarnow, 2014), we
were unable to demonstrate this experimentally (Figure S1D).
Importantly, we confirmed that miR-122 no longer influences
the stability of HJ3–5 RNA in Xrn1-depleted cells (Figure S1F).Cell Host &Moreover, miR-122 supplementation increased the abundance
of previously synthesized nascent RNA detected in control cells,
but not in Xrn1-depleted cells (Figure S2). Collectively, these
data provide strong justification for our use of Xrn1-depleted
cells in the experiments described here.
While supplementing infected cells with exogenous miR-122
enhances the expression of HCV proteins (Jangra et al., 2010),
the extent to which this results from a direct effect of miR-122
on the viral IRES or is secondary to stabilization of the genome
or increased genome synthesis has been unresolved (Conrad
et al., 2013; Henke et al., 2008; Roberts et al., 2011; Shimakami
et al., 2012a). By developing methods allowing a direct compar-
ison of the influence of miR-122 on viral RNA synthesis versus
the synthesis of an essential viral nonstructural protein, NS5A,
we have been able to show that transfection of duplex miR-
122 induces significant increases in viral RNA synthesis in
Xrn1-depleted cells prior to any increase in viral protein synthesisMicrobe 17, 217–228, February 11, 2015 ª2015 Elsevier Inc. 223
Figure 6. Polysome Analysis of Lysates from Infected, Xrn1-Depleted Cells Supplemented with miRNAs or Treated with Puromycin
(A) HCV-infected cells were harvested for polysome analysis (see Supplemental Experimental Procedures) following depletion of Xrn1 and transfection with miR-
122 (red) or miR-124 (black) for 1 or 2 hr as outlined schematically in Figure 2A. Graphs on the left, from top to bottom, represent A254 and the distribution of HCV
RNA and b-actinmRNA across 16 gradient fractions. RNA results aremean ± SEMpercent of the total of that RNA in gradients from two independent experiments
where cells were harvested 1 hr after miRNA transfection. On the right is the ratio of the cumulative percent RNA in fractions 7–9 divided by that in fractions 11–13
(polysomes) in gradients of lysates collected 1–2 hr after supplementation with miR-122 or miR-124. Results shown represent the mean ± SEM from three
gradients in three independent experiments.
(B) Polysome analysis of lysates from cells treated for 3 hr with puromycin (PUR) 50 mg/ml (no miRNA supplementation). Release of RNAs from polysomes is only
partial: lysates were not exposed to high-salt conditions prior to centrifugation, as the intent was to reflect conditions in the puromycin-treated cells shown in
Figure 5. On the right is shown the ratio of percent HCV RNA and actin mRNA in fractions 7–9, divided by the percent in fractions 11–13 (polysomes) in the
gradients shown on the left.
(C) Similar polysome analyses of CLIC4 and CAT1 mRNA in lysates collected 1 hr after transfection of miR-122 or miR-124. For all panels *p < 0.05, **p < 0.01 by
two-sided paired t test; n.s., not significant. See also Figures S5 and S6.(Figure 2D). These data provide strong evidence that miR-122
acts to directly promote HCV RNA synthesis, and that this leads
to secondary increases in viral protein synthesis with subse-
quent expansion of viral replication complexes.
Kinetic analyses of increases in viral RNA and protein abun-
dance following transfection of miR-122 in Xrn1-depleted cells
indicated that there is very tight coupling of HCV translation
and RNA replication (Figures 1C–1E). With some positive-strand224 Cell Host & Microbe 17, 217–228, February 11, 2015 ª2015 ElseRNA viruses, continued protein translation is required for
ongoing synthesis of viral RNAs. For example, poliovirus RNA
synthesis is dependent on translational activity of the viral RNA
(Novak and Kirkegaard, 1994), and continuous protein synthesis
is required for RNA synthesis by the coronavirus mouse hepatitis
virus (Hagemeijer et al., 2012; Shi et al., 1999). Previous data
suggest this is not the case for flaviviruses, including HCV (Shi
et al., 2003; Westaway et al., 1999). We confirm this herevier Inc.
Figure 7. miR-122 Supplementation Does Not Stimulate RNA Synthesis in PCBP2-Depleted Cells
(A) Top: biotin-conjugated wild-type (wt) RNA bait representing the 50 47 nts of H77HCV (Li et al., 2014). TwomiR-122molecules (red font) are shown bound to the
bait (Jopling et al., 2008; Shimakami et al., 2012b). Seed sequence-binding sites are highlighted. Bottom: immunoblots of AGO2, PCBP2, and hnRNP L co-
precipitating with the bait in a pull-down experiment. PCBP2 pull-down is eliminated by pre-annealing the bait with single-stranded miR-122 (but not miR-124).
Input, Huh-7 cell lysate.
(B) Left: mutant RNA baits. Right: immunoblots of AGO2, PCBP2, and hnRNP L co-precipitating with the indicated bait.
(C) Design of experiments to assess impact of PCBP2 depletion on miR-122 stimulation of RNA synthesis. Stably infected cells were transfected twice with
PCBP2-specific (siPCBP2) or control siRNA (siCtrl) prior to labeling with 5-EU and [35S] as in Figure 2A. The cells were not depleted of Xrn1.
(D) Left: immunoblots of NS5A-YFP and PCBP2 in lysates of cells at time of harvest. b-actin was a loading control. Right: quantitative immunoblot analysis.
NS5A-YFP abundance, normalized to b-actin, in siPCBP2-transfected cells was 83% ± 7% that in siCtrl-transfected cells (mean ± SEM, n = 4, p = 0.12 by Mann-
Whitney test).
(E) HCV RNA abundance in lysates of cells at time of harvest. RNA abundance in siPCPB2-transfected cells was 80% ± 4% of siCtrl-transfected cells in two
independent experiments, each involving three technical replicates. **p < 0.01 by Mann-Whitney test.
(F) NS5A-YFP synthesized following miRNA supplementation of PCBP2-depleted versus control cells. Cell lysates collected after 1- or 2-hr labeling were
immunoprecipitated with anti-GFP or isotype control (Ig) antibody, and the precipitates separated by SDS-PAGE. Radiolabeled proteins were visualized with a
phosphorimager.
(G) Phosphorimager quantitation of [35S]-labeled nascent NS5A-YFP following miR-122 (open bar) or miR-124 (shaded bar) supplementation of PCBP2-depleted
versus control cells with a 1- or 2-hr labeling period. NS5A-YFP synthesis was significantly dependent upon PCBP2 depletion, but not miR-122 supplementation
(p < 0.0001 and p = 0.84, respectively, by two-way ANOVA).
(H) Nascent HCV RNA synthesis under the conditions described in (G). Nascent RNA synthesis was significantly dependent upon both PCBP2 depletion andmiR-
122 supplementation (p = 0.02 and p < 0.01, respectively, by two-way ANOVA). For both (G) and (H), results have been normalized tomiR-124-transfected control
(siCtrl-transfected) cells, and represent themean ± SEM from five to six biological replicates in two independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 by
ANOVA with Fisher’s individual least significant difference test.(Figure 5D). Surprisingly, however, our results show that active
protein translation is required for miR-122 to stimulate nascent
HCV RNA synthesis.Cell Host &Based on studies with other positive-strand viruses, we
recently speculated that miR-122 could promote HCV RNA syn-
thesis by forming a complex that acts as a promoter for the viralMicrobe 17, 217–228, February 11, 2015 ª2015 Elsevier Inc. 225
RdRp, or that might facilitate a requirement for cyclization of the
genome prior to negative-strand RNA synthesis (Li et al., 2013a).
We also considered the possibility that amiR-122 complex could
stimulate new positive-strand RNA synthesis by binding the 50
end of the positive-strand component of duplex replication inter-
mediates, thereby promoting strand separation and freeing the
30 end of negative-strand RNA to serve as template for new pos-
itive-strand RNA synthesis (Li et al., 2013a). While these remain
possibilities, none of these hypotheses accounts for why active
protein translation is required for miR-122 to stimulate RNA
synthesis.
An alternative hypothesis that could explain the inability of
miR-122 to stimulate viral RNA synthesis following shutdown
of cellular translation is suggested by the need to regulate the
engagement of viral RNA in translation versus RNA synthesis
during positive-strand RNA virus replication. Since the genomes
of these viruses serve as template for both translation and RNA
synthesis, there is a conflict inherent in the 50-to-30 movement of
translating ribosomes and the 30-to-50 translocation of the RdRp
during negative-strand synthesis (Gamarnik and Andino, 1998).
In the case of poliovirus, translation dominates until the viral pro-
tease becomes sufficiently abundant to cleave PCBP2, which
binds the 50 end of poliovirus RNA and in its intact form promotes
IRES-directed translation (Perera et al., 2007). How HCV regu-
lates the engagement of genomes in translation versus RNA syn-
thesis is not known, but it is unlikely to utilize such an ‘‘on-off’’
switch due to the need to maintain continuous low-level replica-
tion in persistently infected hepatocytes. Puromycin acts to
release translating ribosomes from messenger RNAs, thereby
terminating translation. Similar to previous in vitro studies of
poliovirus replication (Barton et al., 1999), puromycin-induced
release of ribosomes from HCV RNA correlated in the short
term with increased viral RNA synthesis (Figure 5D). In effect,
puromycin induces an artificial switch from translation to
replication.
miR-122 appears to act in a fashion similar to puromycin, facil-
itating a shift in the balance of HCV genomes engaged in trans-
lation versus RNA synthesis. The polysome analysis in Figure 6A
shows that miR-122-induced increases in viral RNA synthesis
are associated with a reproducible shift of viral RNAs from poly-
somes to the monosome fraction. This explains why miR-122
has no effect on RNA synthesis in the presence of puromycin,
when all ribosomes have been released from the RNA, or
following CHX treatment, when they are frozen in place. The
miR-122 effect is only partial; substantial HCV RNA remains
bound to polysomes and continues to be translated in the pres-
ence of miR-122 (Li et al., 2013a). However, miR-122 increases
the fraction of RNA genomes available to template newRNA syn-
thesis. It seems likely that miR-122 accomplishes this, at least in
part, by displacing PCBP2 from the viral RNA (Figure 7) (Li et al.,
2014). This may reduce the cyclization state of the viral RNA
(Wang et al., 2011), potentially freeing 30 UTR sequences for in-
teractions with the replicase. Additional mechanisms may also
be involved, including changes in the tertiary structure of the viral
IRES (Mortimer and Doudna, 2013). The AGO2 complex re-
cruited to HCV RNA by miR-122 could also function to reduce
translation, as miRNA-induced silencing complexes normally
do. Further efforts will be required to answer these questions,
and to learn whether miR-122 promotes negative-strand or pos-226 Cell Host & Microbe 17, 217–228, February 11, 2015 ª2015 Elseitive-strand viral RNA synthesis. However, the data presented
here reveal amechanism bywhich amiRNA regulates replication
of a positive-strand virus by modulating the binding of cellular
proteins to the viral RNA and controlling the balance between
engagement of the RNA in protein translation versus viral RNA
synthesis.
EXPERIMENTAL PROCEDURES
Cells and Reagents
Huh-7, Huh-7.5, and FT3–7 cells were maintained as described (Jangra et al.,
2010; Shimakami et al., 2011). PSI-6130 (b-D-20-deoxy-20-fluoro-20-C-methyl-
cytidine) (Stuyver et al., 2006) and SOF (20-deoxy-20-a-fluoro-b-C-methyluri-
dine-50-monophosphate) (Murakami et al., 2010) were kindly provided by
Angela Lam (Pharmasset, Princeton) and Ann Sluder (Scynexis, Research Tri-
angle Park). Final dilutions contained 0.5% DMSO. CHX and puromycin were
from Sigma-Aldrich (St. Louis) and InvivoGen (San Diego), respectively.
Virus Infections
HCV infections were initiated by electroporation of cells with RNA transcribed
in vitro from amolecular clone, pHJ3–5, and (as a control) its replication-defec-
tive variant, pHJ3–5/GND (Yi et al., 2009). pHJ3–5/Gluc2A contains an in-
frame insertion of the Gaussia princeps luciferase (GLuc) sequence between
p7 and NS2 (Shimakami et al., 2011). pHJ3–5/NS5AYFP is a related plasmid
in which the enhanced YFP sequence has been inserted in-frame within the
NS5A protein-coding sequence (Ma et al., 2011). In vitro transcribed RNA
was electroporated into 5 3 106 Huh-7, Huh-7.5, or FT3–7 cells as described
below. FT3–7 cells were cultured until more than 80% of cells were positive for
core antigen expression by immunofluorescence assay. YFP-expressing
Huh-7 cells were sorted by flow cytometry until nearly 100% of the cells
were stably YFP positive.
RNA Oligonucleotides
Mature miRNA duplexes were generated by annealing equimolar amounts of
guide and passenger strands. miR-122 and miR-124 were always transfected
as duplexes, while anti-miR-122 and anti-random were transfected as single-
stranded oligonucleotides. Sources and sequences of oligonucleotides are
described in the Supplemental Experimental Procedures.
In Vitro RNA Transcription and Transfection
RNA transcripts were synthesized in vitro as described (Shimakami et al.,
2011). For transfection, 5–10 mg RNA was mixed with 5 3 106 cells in a
4-mm cuvette and pulsed once at 250 V, 950 mF, and 50 U in a Gene Pulser
Xcell Total System (Bio-Rad, Hercules). miRNA duplexes (50 nM), single-
stranded oligonucleotides (50 nM), or siRNAs (20 nM) were transfected into
cells using Lipofectamine RNAiMAX (Life Technologies, Carlsbad) according
to the manufacturer’s recommended procedures.
Immunoblots
Immunoblotting was carried out using standard methods with primary and
IRDye-conjugated secondary antibodies (described in the Supplemental
Experimental Procedures). Protein bands were visualized and quantified by
densitometry with an Odyssey Infrared Imaging System (Li-Cor Biosciences,
Lincoln).
HCV 50 UTR-Protein Interactions
Biotin-conjugated RNAs representing the 50 47 nts of the HCV genome were
chemically synthesized and used in pull-down experiments with hepatoma
cell lysates as described previously (Li et al., 2014).
Quantification of miR-122 Co-Immunoprecipitating with AGO2
Cells were lysed in buffer containing 25 mM Tris-HCl (pH 7.4), 150 mM KCl,
5 mM EDTA, 1% Triton X-100, 5 mM dithiothreitol, protease inhibitor cocktail
(Roche), and 100 U/ml RNaseOUT (Life Technologies). Lysates were pre-
cleared with 20 ml of Protein G Sepharose beads (GE Healthcare) for 1 hr at
4C, then incubated with mouse monoclonal anti-AGO2 (MBL International)
or isotype control IgG at 4C for 2 hr, followed by addition of 20 ml of Proteinvier Inc.
G Sepharose beads for 1 hr. Sepharose beads were washed six times in lysis
buffer, and total RNA extracted using themiRCURY RNA Isolation Kit (Exiqon).
miR-122 was quantified using themiRCURY LNAUniversal RTmicroRNA PCR
system and hsa-miR-122-5p LNA PCR primer set (Exiqon).
Metabolic Labeling and Measurement of Nascent HCV RNA and
Protein Synthesis
Nascent RNA transcripts were quantified using the Click-iT Nascent RNA
Capture Kit (Life Technologies) with modifications to the manufacturer’s pro-
tocol. Cells were pulsed with 0.5 mM 5-EU for 1 hr, 0.3 mM 5-EU for 2 hr, or
0.2 mM 5-EU for more than 3 hr to incorporate 5-EU into newly synthesized
RNA. Cells were then washed with PBS, and total RNA extracted using the
RNeasy Mini Kit (QIAGEN, Venlo). Total RNA 5 mg and 0.5 mM biotin azide
were used in a copper-catalyzed click reaction to conjugate biotin to
5-EU-labeled RNA. Following precipitation, the RNA was dissolved in 50 ml
of RNase-free water. Biotin-conjugated 5-EU-RNA was isolated from 3 mg
total RNA on streptavidin magnetic beads and used as a template for reverse
transcription. cDNA synthesis was primed with an HJ3–5-specific primer
using the SuperScript III First-Strand Synthesis System (Life Technologies),
followed by TaqMan qPCR analysis using iQ Supermix (Bio-Rad) (see Sup-
plemental Experimental Procedures for additional details). Nascent HCV
RNA abundance was normalized to the total RNA (3 mg) used to capture
nascent RNA transcripts on streptavidin magnetic beads, and is expressed
as ‘‘copies/mg total RNA.’’
For [35S] labeling, cells were cultured in methionine- and cysteine-deficient
DMEM (Life Technologies) for 2 hr prior to the addition of 200 mCi/well of
Express Protein Labeling Mix (PerkinElmer, Waltham). After incubation for
1–12 hr, cells were washed with PBS and lysed with 500 ml/well of lysis buffer
(20 mM Tris-HCl [pH 7.4] containing 150 mM NaCl, 1% Triton X-100, 0.05%
SDS, and 10% glycerol) supplemented with 50 mM NaF, 5 mM Na3VO4, and
complete protease inhibitor cocktail (Roche, Mannheim). Cells were disrup-
ted by 20 passages through a 25-gauge needle, and protein concentrations
determined by Bradford Protein Assay (Bio-Rad). Lysates (130 mg total pro-
tein) were precleared with 10 ml of Protein G Agarose beads (Life Technolo-
gies) for 1 hr at 4C, then incubated with rabbit anti-GFP or isotype control
overnight at 4C. Protein G Agarose beads (10 ml) were added to the lysate,
incubated for 2 hr at 4C, washed five times with 0.5 ml lysis buffer, then
boiled for 5 min in 20 ml SDS sample buffer. Proteins were resolved by
SDS-PAGE and visualized and quantified with a phosphorimager and
ImageQuant software (GE Healthcare, Fairfield). To assess total protein syn-
thesis, 10% of radiolabeled cell lysates were subjected to SDS-PAGE
without immunoprecipitation. Proteins were directly visualized with Sypro
Ruby Protein Gel Stain (Bio-Rad).
Polysome Profiling
3 3 106 HJ3–5/NS5AYFP-infected Huh-7 cells in 10-cm dishes were treated
with puromycin 50 mg/ml for 3 hr, or transfected with miRNAs and incubated
for 1 or 2 hr. Cells were then incubated with CHX 100 mg/ml for 10min, washed
once with PBS containing CHX 100 mg/ml, and mechanically harvested. Cells
were pelleted by low-speed centrifugation, resuspended in 1 ml polysome
lysis buffer (PLB; 140 mM KCl, 5 mM MgCl2, 20 mM Tris-HCl [pH 7.4],
0.01% Triton X-100, 10 mM DTT, 100 mg/ml CHX), then placed on ice for
10 min prior to passage through a 27-gauge needle five times before centrifu-
gation at 1,0003 g. The resulting supernatant was clarified by centrifugation at
16,0003 g, then separated on a linear 10%–50% sucrose gradient prepared in
PLB and centrifuged in an SW40 Ti rotor (Beckman, Brea) for 2 hr at
32,000 rpm at 4C (no brake). A total of 16 fractions were collected from
each gradient with continuous monitoring of absorbance at OD254 (UA-6;
Isco, Lincoln). RNA was extracted from fractions using TRIzol reagent (Life
Technologies) and subjected to cDNA synthesis with random primers, fol-
lowed by qPCR quantitation of HCV, b-actin, CAT1, and CLIC4 cDNA (primer
sequences are provided in Supplemental Experimental Procedures).
Statistical Analysis
Statistical comparisons were carried out by two-tailed Mann-Whitney test
unless otherwise noted. Calculations were made with Prism 5.0c for Mac
OS X software (GraphPad Software, La Jolla). p < 0.05 was considered
significant.Cell Host &SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and Supplemental Experimental
Procedures and can be found with this article online at http://dx.doi.org/10.
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